Pelthos Therapeutics Inc. Research and Development Expense
Pelthos Therapeutics Inc. (PTHS) reported Research and Development Expense of $600.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- Pelthos Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $600.00K, a 16.50% increase year-over-year.
- Pelthos Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $186.00K, a 4.12% decline year-over-year.
- Pelthos Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $374.00K, a 31.23% increase year-over-year.
- Pelthos Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $145.00K, a 65.06% decline year-over-year.
- Pelthos Therapeutics Inc. research and development expense for fiscal 2025 was $1.23M, a 4.16% increase from fiscal 2024.
- Pelthos Therapeutics Inc. research and development expense for fiscal 2024 was $1.18M, a 54.29% decline from fiscal 2023.
- Pelthos Therapeutics Inc. research and development expense for fiscal 2023 was $2.58M, a 558.47% increase from fiscal 2022.
- Pelthos Therapeutics Inc. research and development expense for fiscal 2022 was $391.73K.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $600.00K 10-Q · filed 2026-08-13 | $786.00K 10-Q · filed 2026-08-13 | $1.16M derived: sum of 3 quarters · filed 2026-08-13 | $1.30M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2026-03-31 | $186.00K 10-Q/A · filed 2026-08-13 | $560.00K derived: sum of 2 quarters · filed 2026-08-13 | $705.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.22M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-12-31 | $374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $519.00K derived: sum of 2 quarters · filed 2026-03-19 | $1.03M derived: sum of 3 quarters · filed 2026-08-13 | $1.23M 10-K · filed 2026-03-19 | ||||
| 2025-09-30 | $145.00K 10-Q · filed 2025-11-13 | $660.00K derived: sum of 2 quarters · filed 2026-08-13 | $854.00K 10-Q · filed 2025-11-13 | $1.14M derived: sum of 4 quarters · filed 2026-08-13 | ||||
| 2025-06-30 | $515.00K 10-Q · filed 2026-08-13 | $514.81K 10-Q · filed 2025-08-13 | $709.00K 10-Q · filed 2026-08-13 | $709.11K 10-Q · filed 2025-08-13 | $994.00K derived: sum of 3 quarters · filed 2026-08-13 | $1.41M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $194.00K 10-Q/A · filed 2026-08-13 | $194.30K 10-Q · filed 2025-05-13 | $479.00K derived: sum of 2 quarters · filed 2026-08-13 | $894.00K derived: sum of 3 quarters · filed 2026-08-13 | $906.96K derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2024-12-31 | $285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | $700.00K derived: sum of 2 quarters · filed 2026-03-19 | $712.96K derived: sum of 3 quarters · filed 2026-03-19 | $1.18M 10-K · filed 2026-03-19 | $1.18M 10-K · filed 2025-03-27 | |||
| 2024-09-30 | $415.00K 10-Q · filed 2025-11-13 | $414.64K 10-Q · filed 2024-11-13 | $427.95K derived: sum of 2 quarters · filed 2025-11-13 | $894.00K 10-Q · filed 2025-11-13 | $894.20K 10-Q · filed 2024-11-13 | $3.19M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $12.96K 10-Q · filed 2025-08-13 | $479.56K 10-Q · filed 2025-08-13 | $2.77M derived: sum of 3 quarters · filed 2025-08-13 | $2.82M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $466.61K 10-Q · filed 2025-05-13 | $2.76M derived: sum of 2 quarters · filed 2025-05-13 | $2.81M derived: sum of 3 quarters · filed 2025-05-13 | $2.86M derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | $2.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $2.34M derived: sum of 2 quarters · filed 2025-03-27 | $2.39M derived: sum of 3 quarters · filed 2025-03-27 | $2.58M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $49.13K 10-Q · filed 2024-11-13 | $99.09K derived: sum of 2 quarters · filed 2024-11-13 | $285.20K 10-Q · filed 2024-11-13 | |||||
| 2023-06-30 | $49.95K 10-Q · filed 2024-08-13 | $236.07K 10-Q · filed 2024-08-13 | ||||||
| 2023-03-31 | $186.12K 10-Q · filed 2024-05-15 | |||||||
| 2022-12-31 | $391.73K 10-K · filed 2024-04-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |